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Centrosome-declustering drugs mediate
a two-pronged attack on interphase and mitosis
in supercentrosomal cancer cells
V Pannu1, PCG Rida1, B Celik1, RC Turaga1, A Ogden1, G Cantuaria2, J Gopalakrishnan3 and R Aneja*,1

Classical anti-mitotic drugs have failed to translate their preclinical efficacy into clinical response in human trials. Their clinical
failure has challenged the notion that tumor cells divide frequently at rates comparable to those of cancer cells in vitro and in
xenograft models. Given the preponderance of interphase cells in clinical tumors, we asked whether targeting amplified
centrosomes, which cancer cells carefully preserve in a tightly clustered conformation throughout interphase, presents a superior
chemotherapeutic strategy that sabotages interphase-specific cellular activities, such as migration. Herein we have utilized
supercentrosomal N1E-115 murine neuroblastoma cells as a test-bed to study interphase centrosome declustering induced by
putative declustering agents, such as Reduced-9-bromonoscapine (RedBr-Nos), Griseofulvin and PJ-34. We found tight
‘supercentrosomal’ clusters in the interphase and mitosis of ~ 80% of patients’ tumor cells with excess centrosomes. RedBr-Nos
was the strongest declustering agent with a declustering index of 0.36 and completely dispersed interphase centrosome clusters
in N1E-115 cells. Interphase centrosome declustering caused inhibition of neurite formation, impairment of cell polarization and
Golgi organization, disrupted cellular protrusions and focal adhesion contacts—factors that are crucial prerequisites for
directional migration. Thus our data illustrate an interphase-specific potential anti-migratory role of centrosome-declustering
agents in addition to their previously acknowledged ability to induce spindle multipolarity and mitotic catastrophe. Centrosomedeclustering agents counter centrosome clustering to inhibit directional cell migration in interphase cells and set up multipolar
mitotic catastrophe, suggesting that disbanding the nuclear–centrosome–Golgi axis is a potential anti-metastasis strategy.
Cell Death and Disease (2014) 5, e1538; doi:10.1038/cddis.2014.505; published online 20 November 2014
Unlike in vitro cell cultures, cancer cells in patients’ tumor
tissues have low mitotic indices and proliferation rates.1
Consequently, drugs targeting mitosis demonstrate limited
clinical efficacy, which exposes a fundamental weakness in
the rationale underlying their clinical development. By
contrast, classical microtubule-targeting agents (MTAs), largely believed to act by perturbing mitosis, remain the mainstay
of chemotherapy in the clinic. Given the miniscule population
of mitotic cells in patient tumors,2,3 it stands to reason that
MTAs must target interphase.4 This paradigm shift has
spurred an intense search for novel interphase targets that
combine the ‘ideal’ attributes of cancer-cell selectivity and the
ability to confer vulnerability on a large proportion of
tumor cells.
Centrosomes, the major microtubule-organizing centers
(MTOCs) of cells, are required for accurate cell division, cell
motility and cilia formation.5 The number of centrosomes
within a cell is strictly controlled, and their duplication occurs
only once per cell cycle. Nearly all types of cancer cells have
abnormal numbers of centrosomes,6–8 which correlates with
chromosomal instability during tumorigenesis.9–11 Supernumerary centrosomes in cancer cells can cause spindle
1

multipolarity and thus non-viable progeny. Cancer cells avoid
this outcome by clustering centrosomes to assemble a
pseudo-bipolar mitotic spindle, which yields viable daughter
cells.12 Thus disrupting centrosome clustering may selectively
drive cancer cells with amplified centrosomes to mitotic
catastrophe and apoptosis without affecting normal cells.
The fate and interphase role of the supercentrosomal
cluster inherited by each daughter cell at the end of a
pseudobipolar mitosis is unknown. This is an important
research question, because a majority of cells within tumors
are in interphase and the centrosomes’ command over
microtubule nucleation is crucial for the cellular organization
and motility in interphase. If cancer cells cluster centrosomes
in interphase, then disrupting the cluster could impact
interphase-specific processes, opening up a vital therapeutic
avenue. We envision that centrosome declustering would (a)
derail interphase-specific polarization and migration processes and (b) precipitate multipolar mitosis culminating in
apoptosis. This two-pronged strategy would impact a significantly larger proportion of tumor cells and consign them to
death. Our study herein establishes that centrosomedeclustering drugs (RedBr-Nos, Griseofulvin and PJ-34)
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achieve this two-pronged attack as a unique class of agents
that exhibit multiple cellular activities.
Results
High-grade cancers show robust centrosome amplification and clustering in interphase cells unlike cultured cell
lines. We first assessed whether mitotic and interphase
centrosome clusters are present in samples derived from
high-grade carcinomas of the breast, prostate and colon.
Contrary to the notion that high-grade cancers contain
relatively large proportions of mitotic cells, we found that
o2% of cells harbored mitotic spindles in the tumor samples
examined (n = 8 for each tissue). To assess centrosome
amplification, we counted the number of γ-tubulin dots
associated with 500 nuclei in each tumor sample. In most
cases, centrosomes in tumor areas appeared significantly
larger than centrosomes in adjacent uninvolved tissue. Exact
centrosome numbers in these enlarged centrosomal clusters
were difficult to determine owing to tight centrosome
clustering. We therefore determined centrosomal volumes
by measuring the γ-tubulin spots using the 3-D volume
rendering function in the Zeiss imaging software (Axiovision
LE). If the volume of a centrosome was determined to be
40.76 cubic micron (maximum volume of a centrosome
observed in adjacent uninvolved tissue), it was considered a
case of centrosome amplification. All tissue specimens
showed centrosome amplification in 60–85% of tumor cells
(Figures 1a and bi). In order to assess centrosome clustering
in interphase, we counted centrosomes and measured
centrosomal volumes in 500 interphase nuclei, and nuclei
with 42 γ-tubulin spots or at least one γ-tubulin spot with
increased volume at each MTOC were considered to show
centrosome clustering. More than 75% of interphase cells
exhibited centrosome clustering in all the cancer types
examined (Figures 1a and bii).
In contrast, 6–18% of cancer cells in culture showed mitotic
spindles (data not shown), which was significantly higher than
the corresponding percentage in human tumors. We found
that only 5–20% of cells in cultured cell lines exhibited
amplified centrosomes (Figures 1c, di and dii), a lower
frequency than that observed in patient tumors (Figure 1bi).
We also observed that the multiple centrosomes in cell lines
occurred as a juxtanuclear cluster in interphase cells
(Figure 1c). Thus, while cancer cells in culture exhibit much
higher levels of mitotic activity and lower levels of centrosome
amplification compared with cancer cells within patients’
tumors, cancer cells in culture and in tumors display the
common features of centrosome clustering in interphase as
well as in mitosis.
Murine neuroblastoma cells constitute a good model
system to study centrosome declustering. To identify an
ideal in vitro model system to study interphase-specific
centrosome-declustering events, we evaluated murine neuroblastoma N1E-115 cells. We found that 100% of N1E-115
cells harbor amplified centrosomes (5–20 centrosomes per
cell). We also found that the centrosomal cluster in N1E-115
cells is a melange of single, free-standing mother and
Cell Death and Disease

daughter centrioles and a few canonical centrosomes
(Supplementary Figure S1). We thus wondered how these
cells haul their centrosomal load through the cell cycle
phases to accomplish cell division. In N1E-115 interphase
cells, the multiple centrosomes localized as a distinct
juxtanuclear cluster (Figures 2a and b). However, in ~ 10%
cells, the multiple centrosomes showed significant scattering,
and this feature correlated with chromatin condensation and
the absence of a mitotic spindle. Lamin A/C immunostaining
showed that cells with loose centrosome clusters still had an
intact nuclear membrane. Thus these cells were confirmed to
be in prophase (Figures 2a and b). About 30% of mitotic cells
were in prometaphase (i.e., they lacked a nuclear membrane)
and possessed multipolar spindles with multiple MTOCs at
each spindle pole. Metaphase cells, by contrast, clustered
supernumerary centrosomes into two polar groups to
generate a pseudo-bipolar spindle (Figures 2a and b). The
centrosomes at the poles of the spindle were often arranged
in ‘ring-like’ or ‘V-shaped linear’ configurations (Figures 2a).
Only ~ 20% cells displayed equal centrosome counts at the
two spindle poles. CREST antibody labeling revealed that,
in metaphase cells, the kinetochores did not line up
immaculately along the spindle equator perhaps due to
widespread merotelic attachments (Figure 2c). Centrosomes
remained clustered at the two spindle poles through
anaphase, and the occurrence of occasional lagging chromosomes indicated chromosome missegregation (Figure 2d).
Telophase was marked by nuclear envelope reassembly
around the decondensing chromatin and the inheritance of a
juxtanuclear centrosomal cluster by each daughter cell
(Figures 2a and b). These observations indicated that
murine N1E-115 cells are a great model system to study
centrosome clustering and declustering as they show both
interphase and mitotic centrosome clustering similar to
patient tumor cells.
In order to probe the mechanisms facilitating interphase
clustering in N1E-115 cells, we examined the involvement of
two major microtubule motors (human spleen embryonic
tissue and testis (HSET) and dynein) in centrosome clustering
in interphasic and mitotic N1E-115 cells. We found that siRNA
knockdown of the kinesin-14 protein KifC1/HSET resulted in
robust mitotic declustering generating ~ 65% multipolar mitotic
cells, but negligible interphase declustering (15% as compared with 12% in vehicle-treated controls; Supplementary
Figure S2). However, dynein inhibition by ciliobrevin treatment
demonstrated substantial scattering of interphase centrosomal clusters (~50%) and considerable mitotic declustering
(~35%) (Supplementary Figure S2). Based on these data,
it seems that, while HSET is crucially involved in
mitotic centrosome clustering, dynein has the major role in
maintaining the centrosomal cluster during the subsequent
interphase.
Centrosome-declustering agents disperse interphase
clusters and set the stage for a catastrophic mitosis.
Given the limited mitotic populations in human cancers,
centrosome declustering during mitosis alone would fail to
achieve sufficient elimination of cancer cells. On the other
hand, interphase declustering may not only prime the cell for
catastrophic mitosis but also ensure disruption of interphase-
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Figure 1 Clinical tumors show rampant centrosome amplification and clustering in interphase cells. (a) Representative immunofluorescence confocal micrographs showing
centrosome amplification and clustering status in normal adjacent (left panel) and tumor tissues (right panel) from 10 patients of each cancer type. Insets show clustered
centrosomes in representative mitotic cells (top inset) and interphase (bottom inset) in tumor samples and normal centrosomes in the normal samples. White arrows depict
centrosome clusters in interphase cells. Centrosomes and microtubules were visualized by immunostaining for γ-tubulin (green) and α-tubulin (red), respectively. DNA was
4,6-diamidino-2-phenylindole (DAPI) stained (blue). (bi and bii) Quantitative bar graphs representing the percentage of centrosome amplification and the percentage of
interphase cells with amplified centrosomes that exhibit centrosome clustering, respectively, in the corresponding patient tissue samples. Centrosomes were counted in
interphase cells from randomly selected fields totaling at least 200 cells per sample. (c) Representative immunofluorescence confocal micrographs showing centrosome
amplification and clustering status during interphase in MCF-10A, MDA-MB-231, PC-3 and HT-29 cell lines. Insets show amplified and clustered/declustered centrosomes
in interphase cells. Centrosomes and microtubules were visualized by immunostaining for γ-tubulin (green) and α-tubulin (red), respectively. DNA was DAPI stained (blue).
(di and dii) Quantitative bar graphs representing the percentage of centrosome amplification and the percentage of cells with amplified centrosomes that exhibit centrosome
clustering, respectively, in the corresponding cell lines. Centrosomes were counted in interphase cells from randomly selected fields totaling at least 200 cells per cell line.
Po0.05. Scale bar, 5 μm. BC = breast cancer, PC = prostate cancer, COL = colon cancer
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Figure 2 Cell cycle phase characterization of N1E-115 cells. (a) Representative immunofluorescence confocal micrographs depicting centrosome status in all cell cycle
phases of N1E-115 cells. N1E-115 cells in interphase possess an enormous number of centrosomes as evident by γ-tubulin immunostaining (green). We acquired images as zstacks with the slice interval of 0.40 μm. Z-stack slices encompassing the entire depth of the cell were then merged, and γ-tubulin-positive spots were counted in interphase cells
from randomly selected fields totaling 200 interphase cells. (b) Representative immunofluorescence confocal micrographs showing lamin A/C staining (red) across all cell cycle
phases to visualize nuclear membrane in order to distinguish interphase declustering from prophase scattering of centrosome cluster. (c) Confocal micrograph of a metaphase
cell stained with CREST antibodies (white), antibodies against α-tubulin (red) and γ-tubulin (green) and 4,6-diamidino-2-phenylindole (DAPI; blue) to detect microtubulekinetochore attachments and DNA in a pseudobipolar mitotic spindle. (d) Representative micrograph of an anaphase cell immunostained for α-tubulin (red), γ-tubulin (green) and
DAPI (blue) showing lagging chromosomes. Scale bar, 5 μm
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specific cellular processes that undergird migration. Thus we
investigated how declustering agents affect centrosome
clustering during interphase. We tested three declustering
drugs (RedBr-Nos, Griseofulvin and PJ-34)13–17 and compared them with Paclitaxel, a tubulin-polymerizing drug.
RedBr-Nos, Griseofulvin and Paclitaxel are known to bind
tubulin18–20 but PJ-34 is a poly-ADP-ribose polymerase
inhibitor with no known tubulin-binding property. However,
they share common phenotypes, such as mitotic arrest and
multipolar mitoses.13–17,21 We found N1E-115 cells to be
more sensitive to these drugs compared with other cancer
cell lines (for instance, MDA-MB-231, HeLa) with IC50 values
ranging between 0.05 μM for Paclitaxel and 25 μM for
Griseofulvin (data not shown). To evaluate their effect on
interphase clustering, we treated N1E-115 cells with drugs at
their respective IC50 concentrations for 0, 3, 6 and 9 h and coimmunostained for γ-tubulin and α-tubulin to evaluate
centrosomal spread and microtubule nucleation status,
respectively (Figure 3a). RedBr-Nos and Griseofulvin inflicted
more severe interphase declustering compared with PJ-34
and Paclitaxel. We also verified the cell cycle phases via
lamin A/C immunostaining to distinguish interphase declustering events from prophase centrosomal spread. To quantitate the spread of the interphase centrosomal cluster, we
generated a 3-D reconstruction of z-stack images of 25
randomly-selected interphase cells from the 6-h treatment
group of each drug. By defining an ROI (region of interest)
around the interphase centrosomal cluster, we calculated
volume of the cluster spread using the Volocity software as
shown in Figure 3bi. Likewise, defining an ROI using the cell
periphery provided the cell volume. We defined the interphase declustering index (DI) for each drug as the ratio of the
average volume of clusters to the average volume of the
corresponding cell. Quantitative evaluation of DI revealed
RedBr-Nos as the strongest declustering agent (DI = 0.36),
followed by Griseofulvin (DI = 0.28) and PJ-34 (0.14).
Paclitaxel showed the least declustering effect with a DI of
0.08 as compared with 0.02 in control cells (Figure 3bii). We
also found that dispersal of the interphase centrosome
cluster precipitated multipolar mitoses in the treated cells
(Figure 3c). Again, the proportion of multipolar cells was
higher in RedBr-Nos- and Griseofulvin-treated cells as
compared with cells treated with PJ-34 and Paclitaxel, which
mirrored the trend in interphase declustering (Figure 3c).
These observations suggest that interphase declustering of
centrosomes compels cells into catastrophic multipolar
mitoses.
Centrosome declustering in interphase disrupts Golgi
coalescence and inhibits migration. The Golgi, which is
primarily responsible for posttranslational modification and
protein sorting, also functions as an MTOC.22 It has been
hypothesized that supernumerary centrosomes may better
organize the Golgi to enhance directional cell migration.23 We
therefore investigated what happens to the Golgi upon
declustering drug-induced dispersal of the interphase centrosomal cluster. We co-immunostained drug-treated cells for
GM130 (a cis-Golgi matrix protein crucial for maintaining its
structure) and γ-tubulin. Following treatment with declustering
drugs, the interphase Golgi complex fragmented, and the

distribution of Golgi fragments closely mimicked scattering of
the centrosomal cluster, with the most robust effect seen with
RedBr-Nos and Griseofulvin (Figure 3d).
Research suggests that Golgi-derived microtubules are not
sufficient to preserve cell polarization; instead, they need to
act in concert with the centrosome to establish and maintain
cell polarization.24 In cancer cells harboring a supercentrosomal cluster, we predict that disrupting the cytoskeletal and
organellar framework organized by a strongly polarizing
supercentrosomal cluster will present a setback to the
mechanical thrust that such a cluster can empower a migrating
cell with; this in turn, we predict, will lead to impaired
directional migration. As a surrogate for the polarization that
underlies directional migration, we decided to examine
neuritogenesis, a process in nerve cells involving the
extension of polarized, elongated neurites. N1E-115 cells
usually extend only one major neurite per cell, which can vary
in length from 5 to 500 μm. The growth cones of the neurites
serve as primary focal points of motility. We evaluated the
effect of declustering agents on cell motility by assessing
the length and frequency of neurites formed in a serum-free
medium on a laminin-coated surface. Neurite growth under
these conditions is linear for up to 24 h, reaching a maximum
around 36–48 h after plating. Phase-contrast imaging showed
the presence of several elongated (10–200 μm long) neurites
upon 48 h of serum starvation (Figure 4bi). We observed 70–
80% inhibition of neurite extension when treated with RedBrNos and Griseofulvin and moderate inhibition with PJ-34 and
Paclitaxel treatment (Figures 4a and bii). Confocal imaging
confirmed that inhibition of neurite formation was accompanied by dispersal of the interphase centrosome cluster, which
is normally situated near the base of the tubulin-rich neurite
shaft (Figure 4c).
In order to establish whether Golgi-dependent vesicular
trafficking lies downstream of interphase centrosome clustering during cell polarization and neuritogenesis in N1E-115
cells, we studied the effect of centrosome-declusteringindependent Golgi scattering on neuritogenesis. To accomplish this, we used CLASP1 siRNA to disrupt the Golginucleated microtubules (Figure 4di), thus disarraying the
directionality of post-Golgi vesicular trafficking but leaving the
centrosome cluster intact, and evaluated whether these cells
can generate neurites. We observed ~ 50% Golgi scattering
upon CLASP1 knockdown (Figure 4dii). We observed that
cells with CLASP1 siRNA formed significantly fewer neurites
compared with control cells (Figure 4diii,Supplementary
Figure S3C). This observation suggests that (i) disruption of
Golgi network impedes Golgi polarization-dependent neuritogenesis, and (ii) Golgi complex integrity and polarized postGolgi trafficking lie downstream of interphase centrosome
clustering.
The spatio-temporal arrangement of Golgi apparatus
serves as a geometrical regulator of cell migration as well as
neurite extension. Thus we wanted to determine whether Golgi
disruption upon CLASP1 knockdown affects cell shape and
cell adhesion, modulation of which are crucial for cell migration
as a precursory step for neurite extension in N1E-115 cells.
We observed significant shift in the morphology of cells
from majorly mesenchymal-like cell shape in cells transfected
with control vector to largely amoeboid-like and more
Cell Death and Disease
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Figure 3 Interphase declustering induced by centrosome-declustering agents. (a) Confocal micrographs showing interphase declustering induced by 6-h treatment with
RedBr-Nos (10 μM), Griseofulvin (50 μM), PJ-34 (25 μM) and Paclitaxel (0.1 μM). The percentages indicate proportion of interphase cells with declustered centrosomes. (bi) 3-D
representation and quantitative volume analysis of control and drug-treated interphase cells using the Volocity 6.3 software. Cells were co-immunostained for lamin A/C (red) and
γ-tubulin (green), and z-stacks were acquired with a 0.35 μm z-step. Z-stack slices were then used to construct a 3-D image, and ROIs were defined to generate DI
measurements. (bii) Quantitative bar graph representing the DI of the four drugs. Po0.05. (c) Confocal micrographs showing spindle multipolarity induced by 18h treatment with
declustering agents RedBr-Nos (10 μM), Griseofulvin (50 μM), PJ-34 (25 μM) and Paclitaxel (0.1 μM). Cells were co-immunostained for α-tubulin (red) and γ-tubulin (green).
The percentages indicate proportion of mitotic cells with declustered centrosomes. (d) Confocal micrographs showing Golgi dispersal concomitant with interphase declustering
upon 6-h treatment with all the four declustering agents at the stated concentrations. Cells were co-immunostained for GM130 (red) and γ-tubulin (green). DNA was DAPI
(4,6-diamidino-2-phenylindole) stained. Scale bar, 5 μm

‘rounded’ cell shape in CLASP1 knockdown cells. This shift in
cell morphology indicates changes in cell-substrate adhesion
properties as a result of Golgi dispersal, which was
confirmed by the reduction in vinculin localization at distinct
Cell Death and Disease

adhesion focal points in CLASP1 siRNA cells (Supplementary
Figure S3).
Vinculin stabilizes cell-substrate contacts in neuronal cells
undergoing neuritogenesis,25 and activation by actin-binding
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Figure 4 Inhibition of neuritogenesis by centrosome-declustering agents. (a) Phase-contrast images of N1E-115 cells in SS medium showing neurite formation after 48 h of
SS or with RedBr-Nos (5 μM), Griseofulvin (10 μM), PJ-34 (10 μM) and Paclitaxel (0.05 μM) treatment. Scale bar, 10 μm. (bi and bii) Quantitative bar graphs representing the
average length of neurites and the percentage of population of cells showing neurite length 410 μm, respectively. Hundred cells were counted in each case. Po0.05.
(c) Confocal micrographs showing neurite outgrowth after 48 h without SS, with SS or SS along with drug treatment, respectively. Cells were co-immunostained for α-tubulin (red)
and γ-tubulin (green). DNA was 4,6-diamidino-2-phenylindole (DAPI) stained. (di) Immunoblot showing the CLASP1 expression levels in control and CLASP1 siRNA-transfected
N1E-115 cells. (dii) Confocal micrographs showing Golgi network immunostained for GM130 (red) and centrosome cluster immunostained for γ-tubulin (green) in control and
CLASP1 siRNA-transfected N1E-115 cells. (diii) Confocal micrographs showing neurite outgrowth in control and CLASP1 siRNA-transfected N1E-115 cells. (e) Confocal
micrographs showing vinculin localization during neurite outgrowth after 48 h without SS, with SS or SS along with drug treatment, respectively. Cells were stained for F-actin
using rhodamine-phalloidin, immunostained for vinculin (green) and DNA was DAPI stained. Scale bar, 5 μm

proteins mobilizes vinculin to focal adhesions.26,27 We therefore determined the localization of vinculin in the neurite
extensions and the effect of declustering agents on its
localization. To this end, we immunostained cells for vinculin
and stained F-actin using rhodamine-phalloidin. Cells in
serum-supplemented medium showed vinculin localization

at focal adhesions with very little internalized vinculin. Upon
serum starvation for 48 h, most of the vinculin was localized to
the neurite growth cones. However, upon treatment of serumstarved (SS) cells with RedBr-Nos and Griseofulvin, we
observed complete internalization of vinculin and complete
loss of focal adhesion points. The observed effect was less
Cell Death and Disease
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severe with PJ-34 and Paclitaxel (Figure 4e). Centrosomedeclustering drugs thus impair cell polarization and neurite
formation and the localization of vinculin, a key player in the
establishment of cell-substrate contacts. In order to support
our rationale that the dispersion of centrosomal clusters in
interphase is directly responsible for anti-migratory effects of
these drugs and are not merely side effects of the drugs, we
showed that the declustering agents were comparatively less
affective in disrupting neuritogenesis of mouse neuroblastoma
cells, Neuro-2a (harboring much lesser degree of centrosome
amplification) (data shown in Figure S4).
These observations underscore the immense clinical
potential of centrosome declustering as a selective therapy
for cancer cells harboring excess centrosomes, without
affecting cells with normal centrosome content.
Inhibition of migration results in interphase cell death or
pushes cells into catastrophic mitosis. Several studies
suggest an intrinsic, inverse relationship between cell
migration and cell proliferation. This concept that cells exist
in mutually exclusive cellular states that either permit motility
or mitotic activity is evidenced by numerous in vitro and
in vivo studies28 and is referred to as ‘Go-or-Grow’.29 We thus
explored whether inhibiting migration via declustering drug
treatment of SS N1E-115 cells enhances proliferation
(indicated by Ki67 nuclear immunostaining) or induces
apoptosis (indicated by cleaved caspase-3 immunostaining).
We found a high proportion of Ki67-positive cells upon
treatment with the three declustering drugs (RedBr-Nos,
Griseofulvin and PJ-34) when compared with negligible
number of Ki67-positive SS N1E-115 cells, which should
predominantly be in the G0 phase of the cell cycle (Figure 5,
top panel). These data suggest that declustering drugs cause
more cells to enter the cell cycle under the conditions of
serum starvation. We also wanted to explore whether
apoptosis is induced by interphase declustering and whether
any induced cell death depends on the cells’ passage
through mitosis. Cleaved caspase-3 staining in N1E-115

cells upon treatment with the three drugs for 9 h (a time point
at which the vast majority of cells were in interphase; data not
shown) revealed a higher proportion of caspase-3 positive
interphase cells in the drug-treated cultures compared with
untreated controls, indicating significant induction of cell
death during interphase (Figure 5, bottom panel). Interphasespecific cell death was confirmed with a cell-clock assay
(as described in the Supplementary Data and Supplementary
Figure S5). These observations suggest that disrupting
the supercentrosomal cluster during interphase in
N1E-115 cells (a) induces interphase catastrophe, and (b)
pushes cells into a proliferative mode leading to a catastrophic mitosis. These data thus support the notion that
centrosome-declustering drugs launch a two-pronged attack
on supercentrosomal cells.
Discussion
Majority of cancer patients succumb to cancer due to
metastases for which effective therapeutic options are
currently lacking. Cell migration and invasion are the key cell
biological processes that underlie metastatic dissemination of
cancer cells. With the recent realization that patient tumors are
slow growing with doubling times ranging between 100 and
700 days, the glory of mitosis as a target has faded.1 Most antimitotic drugs have failed so far in clinical trials either owing to
limited efficacy, as most cells in patients’ tumors are not
mitotic, or excessive toxicity; thus interphase is a more
promising chemotherapeutic target.
Recent studies have provided in vitro evidence that
centrosome amplification can cause oncogene-like effects in
promoting cellular invasion in mammary epithelial cells. These
findings assert that structural alteration of the cytoskeleton via
centrosome amplification confers transformation potential to
normal epithelial cells and is directly responsible for tumor
initiation and progression.30 Our study herein is the first to
demonstrate that interphase cancer cells in patients’ tissues
organize their excessive centrosomal load in the form of a

Figure 5 Inhibited migration induces interphase cell death or pushes cells into catastrophic mitosis. (a) Confocal micrographs showing proliferative cells with 24 h of SS or SS
along with RedBr-Nos (5 μM), Griseofulvin (10 μM) and PJ-34 (10 μM) treatment, respectively. Cells were co-immunostained for Ki67 (red) and γ-tubulin (green). The
percentages show proportion of Ki67-positive cells. Scale bar, 5 μm. Confocal micrographs showing cells undergoing apoptosis with 9 h of SS or SS along with RedBr-Nos
(5 μM), Griseofulvin (10 μM) and PJ-34 (10 μM) treatment, respectively. Cells were co-immunostained for cleaved caspase-3 (red) and α-tubulin (green). E percentages show
proportion of cells that stained positive for cleaved caspase-3. Scale bar, 10 μm. (b) Quantitative bar graphs representing the percentage of Ki67- and caspase-3-positive cells
when treated with the respective drugs. Two hundred cells were counted in each case. Po0.05
Cell Death and Disease
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juxtanuclear supercentrosomal cluster. This tight cluster is
maintained throughout interphase and disperses only transiently during prophase followed by reclustering. We show that
untimely dispersal of the supercentrosomal cluster in interphase drastically impacts cytoskeletal and organellar organization; in particular, the Golgi fragments and each dispersed
centrosome carries with it a group of associated Golgi
fragments. As a consequence, the cells are no longer able
to produce neurite extensions and establish proper focal
contacts with the substrate, as needed for directional migration. Interphase clustering of supernumerary centrosomes is
thus a cancer-specific trait that may help cancer cells survive
and migrate. We assert that a powerful strategy to cripple the
migratory agenda of cancer cells is to disrupt the centrosomal
cluster by using centrosome-declustering agents.
The importance of interphase clustering to cancer cells is
spotlighted by the dire consequences of disrupting the
interphase centrosomal cluster. It has been established that
polarity of the Golgi complex and directionality of Golginucleated microtubule arrays are crucial for directional cell
migration. The correct orientation and positioning of the Golgi
apparatus is regulated by the interplay of various factors,
including both centrosome- and Golgi-derived microtubules,
and the binding of A-kinase anchor protein 450 (AKAP450) to
GM130, gamma-tubulin ring complex and dynein–dynactin
complex.31 Our data confirms the scattering of GM130
accompanied by centrosomal cluster scattering upon action
of declustering agents, indicating possible scattering of
AKAP450 as well. Thus disrupting the centrosomal cluster
leads to concurrent scattering of the Golgi apparatus as a
result of which Golgi-derived microtubules and post-Golgi
vesicular trafficking are no longer focused toward the leading
edge, which may have a dramatic effect on directional cell
migration.
Thus centrosome-declustering drugs launch a two-pronged
offensive on supercentrosomal cancer cells in that they not
only scatter the centrosomes through the cytoplasm and
profoundly disrupt the Golgi network to impede cell migration
in interphase but also effectively trap cancer cells in a nonresolvable state that culminates in spindle multipolarity and
metaphase catastrophe in mitosis. We are confident that the
observed phenotypes are triggered by centrosome cluster
dispersal and not due to the drugs used, as the declustering
drugs in our study function through very different mechanisms
and yet produce similar phenotypes.
Our study demonstrates that mouse neuroblastoma
cells N1E-115 are an excellent test-bed for studying the
mechanisms and effects of centrosome clustering and
declustering. These cells, unlike other cell lines, have 100%
centrosome clustering in interphase and ~ 90% ‘pseudobipolar’
spindle formation in mitosis. A ‘good’ declustering drug
should be able to scatter its megacentrosomal cluster into
an unrestricted pool of centrioles in this cell line, consequently
generating excessive spindle multipolarity and severe, deathinducing aneuploidy in daughter cells. The DI as described
for N1E-115 cells in our study can facilitate quantitative
comparison of the efficacy of putative declustering agents.
Based on our data, RedBr-Nos and Griseofulvin showed more
dramatic effects on centrosome declustering and inhibition of
neurite formation as compared with PJ-34 and Paclitaxel.

In sum, our findings reveal the previously underappreciated
aspects of the actions of centrosome-declustering drugs, their
potential application as anti-metastatics and the importance of
interphase as a chemotherapeutic target.
Materials and Methods
Cell culture and transfection. N1E-115 mouse neuroblastoma cells
(CRL-2263) were purchased from the American Type Culture Collection (Manassas,
VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with
4.5 g/l glucose, 1.5 g/l sodium bicarbonate and supplemented with 10% FBS. Cells
were harvested by incubating them in Modified Puck’s Saline D1 solution at room
temperature until the cells detached. MCF-10A cells were cultured in MEGM
medium (Lonza, Basel, Switzerland), MDA-MB-231 and HT-29 cells in DMEM and
PC-3 cells in RPMI medium supplemented with 10% FBS. All lines were tested and
were free of Mycoplasma contamination. N1E-115 cells were transfected with
X-tremeGENE siRNA transfection reagent (Roche, Basel, Switzerland) according to
the manufacturer’s instructions.
Cellular protein preparation, western blotting, immunofluorescence and antibodies and other reagents. Cells were cultured to ~ 70%
confluence, and protein lysates were collected following drug treatment, transfection
or otherwise for western blotting following methods described in previous
publications.13 For immunofluorescence staining, cells grown on glass coverslips
were fixed with cold (−20 °C) methanol or 4% paraformaldehyde (room temperature)
for 10 min and blocked by incubating with 2% bovine serum albumin/PBS/0.05%
Triton X-100 at 37 °C for 1 h. Specific primary antibodies were incubated with
coverslips for 1 h at 37 °C at the recommended dilution followed by 1 : 2000 dilution of
Alexa 488- or 555-conjugated secondary antibodies. Antibodies against γ-tubulin, αtubulin and β-actin were from Sigma (St Louis, MO, USA); cleaved caspase-3 was
from Cell Signaling (Danvers, MA, USA). Alexa 488- or 555-conjugated secondary
antibodies were from Invitrogen (Carlsbad, CA, USA). Anti-Ki67 antibody was from
Abcam (Cambridge, MA, USA). Anti-GM130 antibody was from BD Biosciences (San
Jose, CA, USA). Anti-vinculin antibody was purchased from Millipore (Billerica, MA,
USA). Anti-lamin A/C, anti-centrin-2 and anti-CLASP1 antibodies and horseradish
peroxidase-conjugated secondary antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). CLASP1 siRNA was ordered from Origene (Rockville, MD,
USA). SMARTpool: ON-TARGETplus KIFC1 siRNA (Dharmacon, Pittsburgh, PA,
USA) was used to knockdown HSET in N1E-115 cells.
Electron microscopy. N1E-115 cells were grown on coverslips made of Aclar
film (Electron Microscopy Sciences, Hatfield, PA, USA) and were processed for
electron microscopy as described in previous publication.32
Neurite extension assay. N1E-115 cells were grown on glass coverslips
coated with laminin in 35-mm tissue culture dishes and treated with the respective
drugs diluted in serum-free medium; the cells were then fixed, labeled and
visualized by immunofluorescence microscopy. Cells bearing neurite-like structures
with a length of at least one cell diameter were identified by immunofluorescence
microscopy using an α-tubulin antibody. At least 200 cells were counted for each
condition, and the experiments were repeated three times. The images were taken
using a Ziess LSM 700 confocal microscope (Oberkochen, Germany).
Cell-clock assay. N1E-115 cells were grown to 60–70% confluence and then
treated with Griseofulvin, RedBr-Nos or PJ-34 for 3 and 6 h. After the end of treatment,
the cell-clock dye (prewarmed at 37 °C) was added (150 μl per well in 12-well plate),
and the cells were incubated at 37 °C for 1 h. The dye was washed twice with
prewarmed DMEM medium, and PI was added for 15 min at room temperature and
washed twice with PBS. Fresh medium was added, and the cells were imaged in bright
field (to assess the different phases of cell cycle) and fluorescent (red for PI) channel.
Cell-clock dye is a redox dye, which is readily taken up by live cells. In G1 phase, the
dye in its reduced form is yellow in color, while in the intermediate state it is green (S
and G2 phases) before turning dark blue in the fully oxidized form (mitosis).
Micrographics taken in the bright field channel depicts cells in different cell cycle phases
based on their respective colors.
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